This company is no longer active
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
InDex Pharmaceuticals Holding 관리
관리 기준 확인 2/4
InDex Pharmaceuticals Holding's CEO is Jenny Sundqvist, appointed in Jan 2023, has a tenure of 1.42 years. total yearly compensation is SEK3.54M, comprised of 64% salary and 36% bonuses, including company stock and options. directly owns 0.023% of the company’s shares, worth SEK65.60K. The average tenure of the management team and the board of directors is 4.6 years and 8.4 years respectively.
주요 정보
Jenny Sundqvist
최고 경영자
SEK 3.5m
총 보상
| CEO 급여 비율 | 64.0% |
| CEO 임기 | 1.4yrs |
| CEO 소유권 | 0.02% |
| 경영진 평균 재임 기간 | 4.6yrs |
| 이사회 평균 재임 기간 | 8.4yrs |
최근 관리 업데이트
Recent updates
Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost
Jun 13
Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce
Apr 28We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate
Jul 11We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Jan 21We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Aug 31Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation
Mar 29InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.
Feb 04
How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?
Dec 21CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -SEK 56m |
| Dec 31 2023 | SEK 4m | SEK 2m | -SEK 95m |
보상 대 시장: Jenny's total compensation ($USD338.03K) is above average for companies of similar size in the Swedish market ($USD256.68K).
보상과 수익: Insufficient data to compare Jenny's compensation with company performance.
CEO
Jenny Sundqvist (53 yo)
1.4yrs
테뉴어
SEK 3,543,000
보상
Ms. Jenny Sundqvist serves as Chief Executive Officer of InDex Pharmaceuticals Holding AB (publ) since January 01, 2023. She served as Chief Commercial Officer of Isofol Medical AB (publ) from January 1, 2...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chief Executive Officer | 1.4yrs | SEK 3.54m | 0.023% SEK 65.6k | |
| Deputy CEO & Chief Financial Officer | 7.1yrs | SEK 2.80m | 0.073% SEK 209.8k | |
| Chief Scientific Officer | 2.1yrs | 데이터 없음 | 0.0017% SEK 4.9k | |
| Head of Regulatory Affairs | 11.4yrs | 데이터 없음 | 데이터 없음 |
4.6yrs
평균 재임 기간
56yo
평균 연령
경험이 풍부한 관리: INDEX's management team is considered experienced (4.6 years average tenure).
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Independent Director | 13.4yrs | SEK 235.00k | 0.081% SEK 232.4k | |
| Independent Director | 8.4yrs | SEK 235.00k | 0.077% SEK 219.5k | |
| Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Member of Advisory Board - North America | no data | 데이터 없음 | 데이터 없음 | |
| Member of Advisory Board - Europe | no data | 데이터 없음 | 데이터 없음 | |
| Independent Chairman | 13.4yrs | SEK 500.00k | 0.14% SEK 406.6k | |
| Member of Advisory Board - Europe | no data | 데이터 없음 | 데이터 없음 | |
| Chairman of Advisory Board - Europe | 2yrs | 데이터 없음 | 데이터 없음 | |
| Member of Advisory Board - Europe | no data | 데이터 없음 | 데이터 없음 | |
| Member of Advisory Board - Europe | no data | 데이터 없음 | 데이터 없음 | |
| Member of Advisory Board - Europe | no data | 데이터 없음 | 데이터 없음 | |
| Member of Advisory Board - North America | no data | 데이터 없음 | 데이터 없음 |
8.4yrs
평균 재임 기간
70yo
평균 연령
경험이 풍부한 이사회: INDEX's board of directors are considered experienced (8.4 years average tenure).